PHARMACODYNAMIC RELATIONSHIP BETWEEN PCSK9, ALIROCUMAB, AND LDL-C LOWERING IN FOUR PHASE 3 ODYSSEY TRIALS WITH/WITHOUT STATIN BACKGROUND

被引：1
|
作者：
Robinson, J. G. [1 ,2 ]
Farnier, M. [3 ]
Kastelein, J. J. [4 ]
Roth, E. M. [5 ]
Taskinen, M. R. [6 ,7 ]
Colhoun, H. M. [8 ]
Brunet, A. [9 ]
DiCioccio, A. T. [10 ]
Lecorps, G. [11 ]
Pordy, R. [12 ]
Baccara-Dinet, M. T. [13 ]
Cannon, C. P. [14 ]
机构：
[1] Univ Iowa, Dept Epidemiol, Iowa City, IA USA
[2] Univ Iowa, Dept Med, Iowa City, IA 52242 USA
[3] Lipid Clin, Point Med, Dijon, France
[4] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[5] Sterling Res Grp NA, Cincinnati, OH USA
[6] Univ Helsinki, Heart & Lung Ctr, Helsinki Univ Hosp, Helsinki, Finland
[7] Res Programs Unit Diabet & Obes, Helsinki, Finland
[8] Univ Dundee, Populat Hlth Sci, Dundee, Scotland
[9] Sanofi, R&D, Paris, France
[10] Regeneron Pharmaceut Inc, Pharmacometr, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[11] Sanofi, R&D Biostat, Paris, France
[12] Regeneron Pharmaceut Inc, Cardiovasc & Metab Therapeut, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[13] Sanofi, Clin Dev, Montpellier, France
[14] Harvard Clin Res Inst NA, Boston, MA USA
来源：
ATHEROSCLEROSIS | 2016年 / 252卷
关键词：
D O I：
10.1016/j.atherosclerosis.2016.07.219
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS16-0634
引用
收藏
页码：E231 / E231
页数：1
相关论文
共 50 条
  • [21] Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE-/- Mice
    Gu, Lili
    Gong, Yaqin
    Zhao, Cheng
    Wang, Yue
    Tian, Qinghua
    Lei, Gaoxin
    Liang, Yalin
    Zhao, Wenfeng
    Tan, Shuhua
    MOLECULES, 2019, 24 (22):
  • [22] Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials
    Siddiqi, H.
    Everett, B. M.
    Rose, L. M.
    Ridker, P. M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3225 - 3225
  • [23] THERAPEUTIC LDL-C LOWERING WITH PCSK9 DIRECTED OLIGONUCLEOTIDE THERAPY (INCLISIRAN) IN A PATIENT WITH FAMILIAL HYPERLIPIDEMIA (FH) REFRACTORY TO PCSK-9 MONOCLONAL ANTIBODY (EVOLOCUMAB)
    Skove, Stephanie
    Anderson, Jeffrey L.
    Le, Viet T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2474 - 2474
  • [24] Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
    Janis, Minna T.
    Tarasov, Kirill
    Ta, Hung Xuan
    Suoniemi, Matti
    Ekroos, Kim
    Hurme, Reini
    Lehtimaki, Terho
    Paiva, Hannu
    Kleber, Marcus E.
    Maerz, Winfried
    Prat, Annik
    Seidah, Nabil G.
    Laaksonen, Reijo
    ATHEROSCLEROSIS, 2013, 228 (02) : 380 - 385
  • [25] Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme
    Roth, E.
    Rosenson, R. S.
    Louie, M. J.
    Mandel, J.
    Patel, M.
    Ray, K. K.
    EUROPEAN HEART JOURNAL, 2017, 38 : 313 - 314
  • [26] Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: Effects of LDL lowering by ezetimibe in the absence of statins
    Hentze, Hannes
    Jensen, Kristian K.
    Chia, Ser Mien
    Johns, Douglas G.
    Shaw, Rachel J.
    Davis, Harry R., Jr.
    Shih, Shian-Jiun
    Wong, Kenny K.
    ATHEROSCLEROSIS, 2013, 231 (01) : 84 - 90
  • [27] Serum PCSK9 Levels Distinguish Individuals Who Do Not Respond to High-Dose Statin Therapy with the Expected Reduction in LDL-C
    Taylor, Beth A.
    Panza, Gregory
    Pescatello, Linda S.
    Chipkin, Stuart
    Gipe, Daniel
    Shao, Weiping
    White, C. Michael
    Thompson, Paul D.
    JOURNAL OF LIPIDS, 2014, 2014
  • [28] Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
    Ray, Kausik K.
    Vallejo-Vaz, Antonio J.
    Ginsberg, Henry N.
    Davidson, Michael H.
    Louie, Michael J.
    Bujas-Bobanovic, Maja
    Minini, Pascal
    Eckel, Robert H.
    Cannon, Christopher P.
    ATHEROSCLEROSIS, 2019, 288 : 194 - 202
  • [29] MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
    Xu, Xiaoding
    Dong, Yunxia
    Ma, Ningning
    Kong, Weiwen
    Yu, Chuwei
    Gong, Likun
    Chen, Jing
    Ren, Jin
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 119
  • [30] Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
    Xie, Wuxiang
    Liu, Jing
    Wang, Wei
    Wang, Miao
    Qi, Yue
    Zhao, Fan
    Sun, Jiayi
    Liu, Jun
    Li, Yan
    Zhao, Dong
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 215 : 293 - 298
12345